If accepted, Epygenix expects to initiate a Phase 1 trial with healthy volunteers by August. The company has also requested fast track designation for EPX-100.

A new drug application is an essential first step in launching a clinical trial; a fast track designation allows for an accelerated FDA review process for treatments that could alleviate serious conditions and fill an unmet medical need.

“This IND filing for EPX-100 is one of the company’s significant development milestones. We will test its safety and efficacy in a prompt manner with an eye toward helping many patients who suffer from this disorder,” Hahn-Jun Lee, M.Sc., PhD, president and CEO of Epygenix Therapeutics, said in a press release.

“We are very pleased to collaborate with Epygenix to support the IND filing for EPX-100, as well as to manage the Phase 1 study in normal volunteers,” said Jules Mitchel, PhD, president at Target Health, the lead regulatory and clinical research organization for the EPX-100 development program.

EPX-100 is a repurposed antihistamine, originally known as clemizole, used to treat itching in the 1950s and 1960s. EPX-100 has shown potential to suppress seizures by modulating serotonin, a mechanism that differs from its antihistaminic properties.

Serotonin is a chemical messenger present in many parts of the brain. Scientists think that people with Dravet syndrome may have alterations in the serotonin signaling pathway, but exact problems are not known. Likewise, precisely how EPX-100 affects serotonin systems in the brain to improve seizures is still unclear.

“The IND filing for EPX-100 is an exciting leap to the clinical stage, and a significant milestone in validating our unique zebrafish-to-human approach to precision medicine,” said Scott C. Baraban, PhD, professor at UC San Francisco and chair of the scientific advisory board at Epygenix Therapeutics.

In April 2017, EPX-100 received the FDA’s orphan drug designation. This program is designed to promote the development of new therapies for rare diseases.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Disclaimer:

Dravet Syndrome News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more